Universität zu Köln

2022

Heitz, F., Weber-Lassalle, K., Ernst, C., Moellenhoff, K., De Gregorio, N., Hauke, J., Dietrich, D., Borde, J., Jackisch, C., Park-Simon, T-W, Hanker, L. C., Pohl-Rescigno, E., Prieske, K., Kommoss, S., Marme, F., Stingl, J. C., Rita, S., Harter, P. and Hahnen, E. (2022). Chemotherapy-induced mutations in genes of clonal hematopoiesis increase the risk of myeloid neoplasms. Geburtshilfe Frauenheilkd., 82 (10). S. E88 - 1. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8804

2021

Tuechler, A., Remy, R., Dick, J., Ernst, C., Bluemcke, B., Lakeman, I. M. M., van Asperen, C. J., Devilee, P., Bredart, A., Rhiem, K. E., Stoppa-Lyonnet, D., Schmutzler, R. K. and Hahnen, E. (2021). Incorporating genetic and non-genetic risk factors in breast cancer risk prediction for healthy women with non-informative genetic test result. Ann. Oncol., 32. S. S1104 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041

2020

Hauke, J., Ernst, C., Fasching, P. A., Jackisch, C., Seither, F., Klare, P., Rhiem, K. E., Schmatloch, S., Huober, J., Stefek, A., Seiler, S., Uleer, C., Doering, G., Schneeweiss, A., Denkert, C., Untch, M., Blohmer, J-U., Schmutzler, R. K., Loibl, S. and Hahnen, E. (2020). Germline mutation status and therapy response in patients with homologous recombination deficient, HER2-negative early breast cancer: Results of the GeparOLA study (NCT02789332). Ann. Oncol., 31. S. S313 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041

2018

Bluemcke, B., Keupp, K., Larsen, M., Baasner, A., Waha, A., Versmold, B., Driesen, J., Buelow, L., Ernst, C., Wappenschmidt, B., Hahnen, E. and Schmutzler, R. (2018). NGS-based detection of copy number variations in hereditary breast- and ovarian cancer germline diagnostics. Eur. J. Hum. Genet., 26. S. 536 - 538. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5438

Keupp, K., Ernst, C., Bluemcke, B., Versmold, B., Waha, A., Driesen, J., Baasner, A., Larsen, M., Buelow, L., Kroeber, S., Altmueller, J., Thiele, H., Nuernberg, P., Wappenschmidt, B., Neidhardt, G., Rhiem, K., Schmutzler, R., Hahnen, E. and Hauke, J. (2018). Next-generation sequencing via TruRisk (R) genepanel reveal high mutation prevalence in additional risk genes in German BRCA1/2-negative breast and ovarian cancer families. Eur. J. Hum. Genet., 26. S. 541 - 543. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5438

Larsen, M., Bluemcke, J., Bluemcke, B., Ernst, C., Keupp, K., Buelow, L., Altmueller, J., Thiele, H., Nuernberg, P., Hahnen, E. and Schmutzler, R. (2018). Association of MUTYH with familial breast and ovarian cancer. Eur. J. Hum. Genet., 26. S. 540 - 541. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5438

Pohl, E., Borde, J., Hauke, J., Schmidt, S., Weber-Lassalle, K., Ernst, C., Niederacher, D., Arnold, N., Hellebrand, H., Meindl, A., Gehrig, A., Schmidt, G., Dutrannoy, V., Kast, K., Hahnen, E. and Schmutzler, R. (2018). Beyond CHEK2 in breast cancer: Search for additional moderately penetrant risk gene variants by analyzing the oligogenic disease course in CHEK2 mutation carriers. Eur. J. Hum. Genet., 26. S. 535 - 537. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5438

2017

Keupp, K., Richters, L., Buelow, L., Kroeber, S., Ernst, C., Bluemcke, B., Versmold, B., Waha, A., Driesen, J., Baasner, A., Altmueller, J., Thiele, H., Nuernberg, P., Wappenschmidt, B., Neidhardt, G., Rhiem, K., Schmutzler, R., Hahnen, E. and Hauke, J. (2017). TruRisk (R) based next-generation sequencing in BRCA1/2-negative breast and ovarian cancer families reveal high mutation prevalence in additional risk genes. Cancer Res., 77. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445